Drug
D0026 | Ciglitazone
| Toxicity | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|
| TRANSMEMBRANE POTENTIAL | 10–50 μM | 3min | male CD-1 mice | isolated liver mitochondria | The electrical transmembrane potential of mitochondria was monitored spectrophotometrically with the cationic dye, rhodamine 123, and monitored at the 505/535 nm. | decrease | p < 0.05, significantly different from the control | 331 |
| OPENING OF PERMEABILITY TRANSITION PORE (PTP) | 10–75 μM | male CD-1 mice | isolated liver mitochondria | Mitochondrial swelling as the indicator of mitochondrial permeability transition (MPT) was estimated from the decrease in absorbance at 540 nm. | induce | 331 | ||
| MEMBRANE POTENTIAL | 8.22±1.60 | human | qHTS-HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | 14.13 | human | HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | 9.92±4.25 | rat | hepatocytes | MMP assay | decrease | IC50 | 163 | |
| OXYGEN CONSUMPTION RATE (OCR) | > 100 μM | 2 minutes | human | HepG2 | Measurement of ECAR | decrease | EC50 | 7 |
| OXYGEN CONSUMPTION RATE (OCR) | > 100 μM | 2 minutes | feline | cardiomyocytes | Measurement of OCR | decrease | EC50 | 7 |
| ECAR | > 100 μM | 2 minutes | human | HepG2 | Measurement of ECAR | increase | EC50 | 7 |
| ECAR | 10 μM | 2 minutes | feline | cardiomyocytes | Measurement of ECAR | increase | EC50 | 7 |
| ACCUMULATION OF CALCIUM | 50 μM | male CD-1 mice | isolated liver mitochondria | Assessment of mitochondrial Ca2+ efflux with arsenazo III at 675/685 nm. | decrease | 331 | ||
| Pictogram | Signal | Statements | Precautionary Statement Codes |
|---|---|---|---|
 |
Warning |
The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory. H361 (100%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity] |
P201, P202, P281, P308+P313, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.) |
| (+-)-5-(p-((1-Methylcyclohexyl)methoxy)benzyl)-2,4-thiazolidinedione | (+/-)-5-[4-(1-Methylcyclohexylmethoxy)benzyl]thiazolidine-2,4-dione | 2,4-Thiazolidinedione, 5-((4-((1-methylcyclohexyl)methoxy)phenyl)methyl)- |
| 2,4-Thiazolidinedione, 5-((4-((1-methylcyclohexyl)methoxy)phenyl)methyl)-, (+-)- | 2,4-Thiazolidinedione, 5-[[4-[(1-methylcyclohexyl)methoxy]phenyl]methyl]- | 5-((4-((1-methylcyclohexyl)methoxy)phenyl)methyl)-4-thiazolidinedione |
| 5-(4-((1-methylcyclohexyl)methoxy)benzyl)thiazolidine-2,4-dione | 5-(4-(1-methylcyclohexylmethoxy)benzyl)thiazolidine-2,4-dione | 5-({4-[(methylcyclohexyl)methoxy]phenyl}methyl)-1,3-thiazolidine-2,4-dione |
| 5-[4-(1-methylcyclohexylmethyloxy)benzyl]thiazolidine-2,4-dione | 5-[[4-[(1-Methylcyclohexyl)methoxy]phenyl]methyl]-2,4-thiazolidinedione | 5-[[4-[(1-methylcyclohexyl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione |
| 5-{4-[(1-methylcyclohexyl)methoxy]benzyl}-1,3-thiazolidine-2,4-dione | 74772-77-3 | ACMC-20emv7 |
| ADD 3878 | ADD-3878 | AKOS000278268 |
| AKOS024257650 | API0002009 | AS-56269 |
| BCBcMAP01_000122 | BDBM50103636 | BML2-F01 |
| BRD-A93000692-001-02-4 | BRD-A93000692-001-03-2 | BSPBio_001575 |
| Bio1_000144 | Bio1_000633 | Bio1_001122 |
| Bio2_000295 | Bio2_000775 | C-20127 |
| C18H23NO3S | CAS-74772-77-3 | CBiol_001858 |
| CC-25778 | CHEBI:64227 | CTK7H5565 |
| Ciglitazona | Ciglitazona [Spanish] | Ciglitazone (USAN/INN) |
| Ciglitazone [USAN:INN] | Ciglitazonum | Ciglitazonum [Latin] |
| Ciglitizone | Ciglitizone, >=98% (HPLC) | D03493 |
| DB-055908 | DB09201 | DSSTox_CID_20757 |
| DSSTox_GSID_40757 | DSSTox_RID_79589 | DTXSID0040757 |
| FT-0602959 | GL8018 | GTPL2711 |
| HMS1361O17 | HMS1791O17 | HMS1989O17 |
| HMS3267N05 | HMS3402O17 | HMS3412E22 |
| HMS3649G06 | HMS3676E22 | IDI1_034045 |
| KBio2_000295 | KBio2_002863 | KBio2_005431 |
| KBio3_000589 | KBio3_000590 | KBioGR_000295 |
| KBioSS_000295 | KS-0000008X | LO4 |
| LS-151334 | MCULE-4419123362 | MFCD00865499 |
| NCGC00025104-02 | NCGC00025104-03 | NCGC00025104-04 |
| NCGC00025104-05 | NCGC00025104-07 | NCGC00025104-08 |
| NCGC00025104-09 | NCGC00164446-01 | Q5119890 |
| SC-50312 | SCHEMBL38185 | SR-01000597400 |
| SR-01000597400-1 | SR-01000597400-3 | SR-01000597400-4 |
| ST079285 | Spectrum5_001949 | TRA0078629 |
| TX-017480 | Tox21 112120 | Tox21_112120 |
| Tox21_112120_1 | U 63287 | U-63287 |
| UPCMLD-DP145 | UPCMLD-DP145:001 | UPCMLD-DP145:002 |
| YZFWTZACSRHJQD-UHFFFAOYSA-N | Z3112 | ZINC000001481754 |
| ciglitazone |
| DrugBank Name | Ciglitazone |
| DrugBank | DB09201 |
| CAS Number | 74772-77-3, 85010-66-8 |
| PubChem Compound | 2750 |
| KEGG Drug | D03493 |
| PubChem.Substance | 310265109 |
| ChEBI | 64227 |
| ChemSpider | 2648 |
| BindingDB | 50103636.0 |
| Wikipedia | Ciglitazone |
1. Chan et al. (2005)